Cytokinetics (CYTK) Prices 10M Share Offering at $27.5/sh

Cytokinetics (CYTK) PT Raised to $26 at Goldman Sachs

Goldman Sachs analyst Graig Suvannavejh raised the price target on Cytokinetics (NASDAQ: CYTK) to $26.00 (from $21.00) while maintaining a Neutral rating.... More

Cytokinetics (CYTK) PT Raised to $40 at Barclays

Barclays analyst Carter Gould raised the price target on Cytokinetics (NASDAQ: CYTK) to $40.00 (from $28.00) while maintaining a Overweight rating.... More

Cytokinetics (CYTK) Announces $200M Proposed Public Offering of Common Stock

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or... More

Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst

Earlier today, Cytokinetics, Inc (NASDAQ: CYTK) announced positive topline results from Cohorts 1 and 2 of Redwood-HCM - the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

Throughout the trial, the CK-274 demonstrated high response rates, significant treatment effects and a favorable safety profile, reporting no serious adverse events attributable to CK-274 and no treatment interruptions occurring.

Reacting to the data readout, H.C. Wainwright & Co's analyst Joseph Pantginis believes the drug delivered on all fronts as expected and demonstrates... More

Cytokinetics (CYTK) PT Raised to $44 at JMP Securities, Following Clinical Business Update

JMP Securities analyst Jason N. Butler raised the price target on Cytokinetics (NASDAQ: CYTK) to $44.00 (from $26.00) while maintaining a Market Outperform rating.

Cytokinetics (CYTK) PT Raised to $42 at Piper Sandler, Following Clinical Business Update

Piper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $42.00 (from $25.00) while maintaining a Overweight rating.

Cytokinetics (CYTK) PT Raised to $53 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $53.00 (from $41.00) while maintaining a Buy rating.

Cytokinetics (CYTK) PT Raised to $54 at Raymond James

Raymond James analyst Dane Leone raised the price target on Cytokinetics (NASDAQ: CYTK) to $54.00 (from $37.00) while maintaining a Outperform rating.

Cytokinetics (CYTK) PT Raised to $48 at Needham & Company

Needham & Company analyst Chad Messer raised the price target on Cytokinetics (NASDAQ: CYTK) to $48.00 (from $33.00) while maintaining a Buy rating.

Pre-Open Stock Movers 07/19: (NRXP) (CYTK) (AEHR) Higher; (RCAT) (NCLH) (CCL) Lower (more...)

Pre-Open Stock Movers:

NRx Pharmaceuticals (Nasdaq: NRXP) 48.9% HIGHER; will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST. The presentation identifies a statistically significant effect of ZYESAMI (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19. In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the... More

Cytokinetics (CYTK) Announces Positive Topline Results of Redwood-HCM

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2... More